AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03723382 — intervention group
Intervention type: OTHER
Intervention: SECRET structured 5 bundles of standard healthcare services
Description: THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
Study NCT03505021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 1 mg capsule for oral administration
Study NCT03505021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for levosimendan
Description: Placebo capsule for oral administration
Study NCT01054742 — intervention group
Intervention type: DRUG
Intervention: Standard of Care PegIntron
Description: Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
Study NCT01054742 — intervention group
Intervention type: DRUG
Intervention: Standard of Care Ribavirin
Description: Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
Study NCT03631836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody
Description: 3 doses of Monoclonal antibody could be tested
Study NCT03631836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: fixed dose of bevacizumab (10 mg/ kg every two weeks)
Study NCT03631836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Evaluate the biomarkers plasma levels during administration of drug
Study NCT03631836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)
Description: Assess antiangiogenic effects by DCE-MRI
Study NCT04010500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no mouthguard
Description: Control (not using mouthguard)
Study NCT04010500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'boil and bite' mouthguard
Description: KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
Study NCT04010500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-fitted mouthguard
Description: The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
Study NCT00218491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 1200mg N-Acetylcysteine
Study NCT00218491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 2400mg N-Acetylcysteine
Study NCT00218491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study NCT02562924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDIHONEY®
Description: MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Topical steroid
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Topical steroid
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline sinus rinse
Description: 8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline sinus rinse
Description: 8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Post-operatively, 40 mg daily for 7 days
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Post-operatively, 40 mg daily for 7 days
Study NCT02562924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
Study NCT02562924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal saline spray
Description: saline nasal mist every hour while awake
Study NCT02562924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline spray
Description: saline nasal mist every hour while awake
Study NCT03312660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic group
Description: Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
Study NCT03312660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
Study NCT01040052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)
Description: 0.5 mL, Intramuscular
Study NCT04523077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: determination of thyroid hormones and antibodies
Description: TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
Study NCT03065348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral whey protein
Description: This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
Study NCT03065348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
Study NCT03065348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Drink
Description: Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal
Study NCT03065348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative hydration
Description: If urine specific gravity is >1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
Study NCT03065348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continous spinal anesthesia
Description: Surgery will be performed under continuous spinal anesthesia without general anesthesia
Study NCT01677806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
Study NCT01677806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative therapy
Description: Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
Study NCT00991523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein
Description: protein
Study NCT00991523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT01920204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin,
Description: Midostaurin, twice daily 100 mg orally, continuously for 6 months
Study NCT02849795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone densitometry
Study NCT02849795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02849795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological analyses
Study NCT02019407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI, CTI block
Description: * PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip.
Study NCT02019407 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PVI
Description: PVI (pulmonary isolation)
Study NCT01876407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity laser for oral mucositis
Study NCT01876407 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity laser for oral mucositis switch off
Description: Low intensity laser for oral mucositis switch off
Study NCT04201925 — intervention group
Intervention type: PROCEDURE
Intervention: upper blepharoplasty
Description: excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
Study NCT01047774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Description: 30-50g of protein powder daily for 2 weeks.
Study NCT01047774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolated milk protein
Description: 30-50g of protein powder daily for 2 weeks.
Study NCT00276172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
Study NCT00938314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
Study NCT00938314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
Study NCT00938314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
Description: hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
Study NCT00938314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
Study NCT03468855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002 topical solution
Description: Topical Solution administered twice daily
Study NCT02822066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
Study NCT04957771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervise and guide regular exercise
Description: Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
Study NCT02587533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia without dopamine
Description: Target hemoglobin oxygen saturation (SpO2) 80%.
Study NCT02587533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia with dopamine
Description: Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
Study NCT02587533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia without dopamine
Description: Nearly complete hemoglobin oxygen saturation.
Study NCT02587533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia with dopamine
Description: Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
Study NCT04509778 — intervention group
Intervention type: OTHER
Intervention: routine clinical treatment
Description: Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
Study NCT01150539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16-week exercise training program
Description: The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
Study NCT01150539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group without PCOS
Description: A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
Study NCT02806323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga practice
Study NCT03496090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: Free diet or free demand, being comparable to the normal or zero hospital diet
Study NCT03496090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive diet
Description: Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
Study NCT01497015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory training
Description: 10 1-hour sessions over 6-8 weeks
Study NCT01497015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speed of processing training
Description: 10 1-hour sessions delivered over 6-8 weeks
Study NCT01497015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: waitlist control
Description: Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
Study NCT02227693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: E5501 (avatrombopag) 20-mg tablets
Study NCT02227693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching 20-mg tablets
Study NCT00846014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study NCT03955133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Reaction ADRe Profile for Polypharmacy
Description: PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
Study NCT03329235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma
Study NCT03329235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: platelet rich plasma
Study NCT03329235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: hyaluronic acid
Study NCT02135692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
Study NCT02135692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
Study NCT00651092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral nasal inferior turbinectomy
Description: the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
Study NCT00651092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic submucosal resection of the inferior turbinates
Description: surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
Study NCT01995071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet
Study NCT01995071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet
Study NCT01995071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT01995071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT00089908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine
Study NCT00089908 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN1delta30
Study NCT02562742 — intervention group
Intervention type: DRUG
Intervention: SOF
Description: SOF 400 mg tablets administered orally once daily
Study NCT02562742 — intervention group
Intervention type: DRUG
Intervention: REB
Description: REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
Study NCT01793155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
Study NCT01793155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator: standard physiotherapy
Description: Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
Study NCT01793155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: standard physiotherapy
Description: Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
Study NCT00706134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken once daily in the morning with a light meal.
Study NCT00706134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Description: Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
Study NCT00706134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
Study NCT00706134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg tablet taken once daily in the morning with a light meal.